News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Duncan Barbara Gayle
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/09/2023 |
4
| Duncan Barbara Gayle (Director) has filed a Form 4 on HALOZYME THERAPEUTICS, INC.|
Txns:
| Granted 8,065 shares
@ $0
Granted 11,371 options to buy
@ $31, valued at
$352.5k
|
|
| 05/04/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/27/2023 |
4
| Duncan Barbara Gayle (Director) has filed a Form 4 on Ovid Therapeutics Inc.|
Txns:
| Granted 15,000 options to buy
@ $2.5, valued at
$37.5k
|
|
| 02/07/2023 |
4
| Duncan Barbara Gayle (Director) has filed a Form 4 on HALOZYME THERAPEUTICS, INC.|
Txns:
| Granted 1,188 shares
@ $0 |
|
| 02/06/2023 |
3
| Duncan Barbara Gayle (Director) has filed a Form 3 on HALOZYME THERAPEUTICS, INC. |
| 07/01/2022 |
4
| Duncan Barbara Gayle (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Granted 500,000 options to buy
@ $0 |
|
| 06/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/22/2022 |
4
| Duncan Barbara Gayle (Director) has filed a Form 4 on Fusion Pharmaceuticals Inc.|
Txns:
| Granted 17,000 options to buy
@ $3.6, valued at
$61.2k
|
|
| 06/21/2022 |
4
| Duncan Barbara Gayle (Director) has filed a Form 4 on Atea Pharmaceuticals, Inc.|
Txns:
| Granted 61,264 options to buy
@ $6.5, valued at
$398.2k
|
|
| 04/12/2022 |
4
| Duncan Barbara Gayle (Director) has filed a Form 4 on Ovid Therapeutics Inc.|
Txns:
| Granted 21,347 options to buy
@ $3.22, valued at
$68.7k
|
|
| 02/04/2022 |
4
| Duncan Barbara Gayle (Director) has filed a Form 4 on Ovid Therapeutics Inc.|
Txns:
| Granted 15,000 options to buy
@ $2.72, valued at
$40.8k
|
|
| 07/02/2021 |
4
| Duncan Barbara Gayle (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Granted 379,788 options to buy
@ $0 |
|
| 06/22/2021 |
4
| Duncan Barbara Gayle (Director) has filed a Form 4 on Jounce Therapeutics, Inc.|
Txns:
| Granted 15,700 options to buy
@ $7.27, valued at
$114.1k
|
|
| 06/21/2021 |
4
| Duncan Barbara Gayle (Director) has filed a Form 4 on Atea Pharmaceuticals, Inc.|
Txns:
| Granted 34,025 options to buy
@ $23.39, valued at
$795.8k
|
|
| 06/11/2021 |
4
| Duncan Barbara Gayle (Director) has filed a Form 4 on Ovid Therapeutics Inc.|
Txns:
| Granted 15,000 options to buy
@ $4.49, valued at
$67.4k
|
|
| 06/07/2021 |
4
| Duncan Barbara Gayle (Director) has filed a Form 4 on Fusion Pharmaceuticals Inc.|
Txns:
| Granted 17,000 options to buy
@ $8.15, valued at
$138.6k
|
|
| 05/18/2021 |
4
| Duncan Barbara Gayle (Director) has filed a Form 4 on Ovid Therapeutics Inc.|
Txns:
| Granted 1,750 options to buy
@ $3.67, valued at
$6.4k
|
|
| 11/03/2020 |
4
| Duncan Barbara Gayle (Director) has filed a Form 4 on Fusion Pharmaceuticals Inc.|
Txns:
| Granted 30,000 options to buy
@ $12.4, valued at
$372k
|
|
| 11/03/2020 |
3
| Duncan Barbara Gayle (Director) has filed a Form 3 on Fusion Pharmaceuticals Inc. |
| 10/30/2020 |
4
| Duncan Barbara Gayle (Director) has filed a Form 4 on Atea Pharmaceuticals, Inc.|
Txns:
| Granted 80,000 options to buy
@ $24, valued at
$1.9M
|
|
| 10/29/2020 |
3
| Duncan Barbara Gayle (Director) has filed a Form 3 on Atea Pharmaceuticals, Inc. |
| 10/23/2020 |
4
| Duncan Barbara Gayle (Director) has filed a Form 4 on IMMUNOMEDICS INC|
Txns:
| Disposed/sold 49,244 shares
@ $0
Disposed/sold 6,540 options to buy
@ $0
Disposed/sold 3,718 restricted stock units
@ $0 |
|
| 09/16/2020 |
4
| Duncan Barbara Gayle (Director) has filed a Form 4 on Jounce Therapeutics, Inc.|
Txns:
| Sold 5,000 shares
@ $9.5, valued at
$47.5k
Sold 5,000 shares
@ $10.5, valued at
$52.5k
Exercised 10,000 options to buy
@ $4.21, valued at
$42.1k
|
|
| 09/15/2020 |
4
| Duncan Barbara Gayle (Director) has filed a Form 4 on IMMUNOMEDICS INC|
Txns:
| Exercised 2,500 options to buy
@ $16.96, valued at
$42.4k
|
|
| 08/20/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/14/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/02/2020 |
4/A
| Duncan Barbara Gayle (Director) has filed a Form 4 on Jounce Therapeutics, Inc.|
Txns:
| Granted 15,700 options to buy
@ $7.58, valued at
$119k
|
|
| 07/01/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/29/2020 |
4
| Duncan Barbara Gayle (Director) has filed a Form 4 on Jounce Therapeutics, Inc.|
Txns:
| Granted 13,550 options to buy
@ $7.58, valued at
$102.7k
|
|
| 06/22/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/08/2020 |
4
| Duncan Barbara Gayle (Director) has filed a Form 4 on Ovid Therapeutics Inc.|
Txns:
| Granted 13,250 options to buy
@ $5.29, valued at
$70.1k
|
|
| 02/05/2020 |
4
| Duncan Barbara Gayle (Director) has filed a Form 4 on Aevi Genomic Medicine, Inc.|
Txns:
| Disposed/sold 59,524 shares
@ $0
Disposed/sold 50,000 options to buy
@ $1.55, valued at
$77.5k
Disposed/sold 20,000 options to buy
@ $1.32, valued at
$26.4k
Disposed/sold 20,000 options to buy
@ $4.83, valued at
$96.6k
Disposed/sold 40,000 options to buy
@ $8.09, valued at
$323.6k
Disposed/sold 10,591 options to buy
@ $2.84, valued at
$30.1k
|
|
| 11/15/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/01/2019 |
4/A
| Duncan Barbara Gayle (Director) has filed a Form 4 on Ovid Therapeutics Inc.|
Txns:
| Granted 5,813 options to buy
@ $1.65, valued at
$9.6k
|
|
|
|
|